Key facts
- It has raised $1.5M across 1 recorded rounds; the latest was Seed Round ($855K) in Apr 2026.
- Notable investors include Polsky Center for Entrepreneurship and Innovation at the University of Chicago, Tulane Business Model Competition, Tulane University Innovation Institute, Tulane Ventures.
- Exactics has filed 1 Form D with the SEC, most recently Jun 2026 ($855K sold to 11 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Exactics
Funding rounds
1 roundsAbout Exactics
Developer of rapid diagnostic tools designed for in-field and at-home detection of infectious diseases. The company offers affordable technology with a focus on underrepresented conditions such as Lyme disease, enabling individuals and healthcare professionals to diagnose infections quickly and support timely treatment.
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2021
- Employees
- 9
- Website
- exacticsbiotech.com/
- Ownership
- Privately Held (backing)
Exactics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Exactics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Exactics in its N-PORT filings yet. We sweep new filings monthly.